Filter posts

On the President’s Drug Cost Plan, Three Important Concerns

Part 3. Restricting access under Medicaid Is not the answer This week, BIO launched a …

The Latest Good News on Prescription Drug Costs

Two-hundred biotech allies from more than 40 different states visited Washington D.C. this week. These …

ICER Comes Under Renewed Scrutiny

As we enter a new and exciting era of medicine, there is an important question …

#BIOCEO18: A Bright Future

“A transformative year in medicine.” That’s how BIO President and CEO Jim Greenwood recently described …

Here We Go Again (But In a Good Way)

“We achieved the lowest drug trend since we began measuring drug trend data in 1993.” …

“A Transformative Year in Medicine”

2017 will be remembered as an exciting year for biopharmaceutical innovation. Not only did we …

Five Questions for the Senate Hearing on Prescription Drugs

On Tuesday, the Senate Committee on Health, Education, Labor, and Pensions will hold its third …

Jim Greenwood Talks Biotech Innovation With Bloomberg Radio

While in Boston this week, BIO CEO Jim Greenwood sat down with Bloomberg Boston Bureau …

What's Driving Health Care Spending? Hint: Not Drug Costs.

With health care costs an important concern for many Americans, a common misperception is the …

New Infographic: The Bayh-Dole Act

$1.3 trillion in economic output. Support for roughly 4.2 million jobs. The creation of more …